NEW YORK – Oncocyte said on Thursday it has closed its planned second investment in Razor Genomics, becoming sole shareholder of the firm, which developed what has now become Oncocyte's first commercial assay, DetermaRx.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.